The SPIDIA consortium has been formed by merging the complementary expertise of the different consortium partners. SPIDIA involves 16 partners from 11 different European countries (DE, AT, IT, SE, CH, NO, DK, FR, CZ, BE and NE). It consists of 7 private research companies (including 4 SMEs and 3 pre-analytical diagnostic tool developers), and 8 public research organisations, including universities (molecular biologists, clinical chemists, spectroscopists, pathologists, etc), hospitals, 3 biobanks, and 1 European Standards Organisation, CEN.
It has adapted overall critical mass of 1567 person-months. All partners are European world-class leaders in their fields of activity, publishing in the best journals and inventing key products for the medical and scientific community. Furthermore, the consortium has been extended by a Club of Interest in order to have an optimal dissemination of the obtained results.
The SPIDIA project is coordinated by QIAGEN GmbH, Germany, a life science company with an extensive know how and expertise in sample preparation and stabilisation of biomolecules. Partner NOVAMEN is responsible for the effective project management of SPIDIA and has long standing experience in research management, project and finance controlling as well as meeting organisation for funded projects.
SPIDIA Partners at EMB Meeting in Graz, October 2012
More information on the individual Partners and our Club of Interest can be found under
Subscribe to our newsletter to receive latest news about the project
Visit our contact form to contact SPIDIA and to submit comments and questions about this website.